Phenotyping and long-term follow up of patients with hyper IgE syndrome
Main Article Content
Keywords
Hyper IgE syndrome, Autosomal dominant, Autosomal recessive, Immunological factors, Genetic defect
Abstract
Introduction and objectives: Long-term follow-up of patients with hyper IgE syndrome (HIES), as a primary immunodeficiency disorder, has been poorly investigated. This study describes common clinical and immunological features of patients with HIES in the last 10 years in Shiraz University of Medical Sciences, Shiraz, Iran.
Methods and patients: In this cross-sectional study, the symptoms and medical records of 18 patients, who were diagnosed with HIES, were observed. Genetic and immunologic study was also performed.
Results: Eighteen patients with the mean age of 13 years old were investigated. Ten patients were detected to have mutations in DOCK8 gene and autosomal recessive HIES (AR-HIES); and four patients were found with STAT3 mutation and autosomal dominant HIES (AD-HIES). So, 14 patients with known genetic results were considered for further data analysis. Food allergy, eczema, viral and skin infections were the major complications of AR-HIES patients. The major clinical complications of AD-HIES patients were pneumonia, skin infections and eczema. Food allergy and viral infection were significantly higher in DOCK8 deficient patients. The most common causes of hospitalization in both AR-HIES and AD-HIES patients were pneumonia, skin infections and sepsis. The most common cause of death was found to be sepsis.
Conclusions: AD-HIES and AR-HIES cannot be differentiated only based on the clinical presentations. Genetic features are also necessary for better diagnosis. This study, summarizing the clinical, immunological and genetic information of the patients with AD-HIES and AR-HIES, may open a way for better diagnosis and management of HIES.
References
2. Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics. 1972;49:59-70.
3. Yong PF, Freeman AF, Engelhardt KR, Holland S, Puck JM, Grimbacher B. An update on the hyper-IgE syndromes. Arthritis Res Ther. 2012;14:228-38.
4. Renner ED, Puck JM, Holland SM, Schmitt M, Weiss M, Frosch M, et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr. 2004;144:93-9.
5. Szczawinska-Poplonyk A, Kycler Z, Pietrucha B, HeropolitanskaPliszka E, Breborowicz A, Gerreth K. The hyperimmunoglobulin E syndrome-clinical manifestation diversity in primary immune deficiency. Orphanet J Rare Dis. 2011;6:76-87.
6. Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. J Clin Immunol. 2015;35:189-98.
7. Chandesris M-O, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012;91:e1-19.
8. Alsum Z, Hawwari A, Alsmadi O, Al-Hissi S, Borrero E, Khalak HG, et al. Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single-center experience of twenty-five patients. J Clin Immunol. 2013;33:55-67.
9. Grimbacher B, Schäffer AA, Holland SM, Davis J, Gallin JI, Malech HL, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet. 1999;65:735-44.
10. Aghamohammadi A, Mohammadinejad P, Abolhassani H, Mirminachi B, Movahedi M, Gharagozlou M, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol. 2014;34:478-90.
11. Rezaei N, Pourpak Z, Aghamohammadi A, Farhoudi A, Movahedi M, Gharagozlou M, et al. Consanguinity in primary immunodeficiency disorders; the report from Iranian Primary Immunodeficiency Registry. Am J Reprod Immunol. 2006;56:145-51.
12. Nabavi M, Arshi S, Bemanian A, Aghamohammadi A, Mansouri M, Hedayat E, et al. Long-term follow-up of ninety-eight Iranian patients with primary immune deficiency in a single tertiary centre. Allergol Immunopathol. 2016;44:322-30.
13. Arshi S, Nabavi M, Bemanian MH, Shakeri R, Taghvaei B, Ghalebaghi B, et al. Phenotyping and follow-up of forty-seven Iranian patients with common variable immunodeficiency. Allergol Immunopathol. 2016;44:226-31.
14. Freeman AF, Holland SM. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr Res. 2009;65:32R-7R.
15. Sowerwine KJ, Holland SM, Freeman AF. Hyper-IgE syndrome update. Ann N Y Acad Sci. 2012;1250:25-32.
16. Esmaeilzadeh H, Nabavi M, Amirzargar AA, Aryan Z, Arshi S, Bemanian MH, et al. HLA-DRB and HLA-DQ genetic variability in patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2015;29:e63-9.
17. Al-Herz W, Ragupathy R, Massaad MJ, Al-Attiyah R, Nanda A, Engelhardt KR, et al. Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait. Clin Immunol. 2012;143:266-72.
18. Netea MG, Schneeberger PM, De Vries E, Kullberg BJ, Van Der Meer JW, Koolen MI. Th1/Th2 cytokine imbalance in a family with hyper-IgE syndrome. Neth J Med. 2002;60:349-53.
19. Borges WG, Augustine NH, Hill HR. Defective interleukin12/interferon- pathway in patients with hyperimmunoglobulinemia E syndrome. J Pediatr. 2000;136:176-80.
20. Hagl B, Heinz V, Schlesinger A, Spielberger BD, SawalleBelohradsky J, Senn-Rauh M, et al. Key findings to expedite the diagnosis of hyper-IgE syndromes in infants and young children. Pediatr Allergy Immunol. 2016;27:177-84.
21. Engelhardt KR, Mcghee S, Winkler S, Sassi A, Woellner C, LopezHerrera G, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009;124:1289-302, e1284.
22. Paulson ML, Freeman AF, Holland SM. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. Curr Opin Allergy Clin Immunol. 2008;8:527-33.
23. Renner ED, Rylaarsdam S, Anover-Sombke ˇ S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T H 17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181-7.
24. Su HC. DOCK8 (Dedicator of cytokinesis 8) deficiency. Curr Opin Allergy Clin Immunol. 2010;10:515-20.
25. Freeman AF, Kleiner DE, Nadiminti H, Davis J, Quezado M, Anderson V, et al. Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol. 2007;119:1234-40.
26. Kumánovics A, Perkins SL, Gilbert H, Cessna MH, Augustine NH, Hill HR. Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation. J Clin Immunol. 2010;30: 886-93.
27. Gatz S, Benninghoff U, Schütz C, Schulz A, Hönig M, Pannicke U, et al. Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation. Bone Marrow Transpl. 2011;46:552-6.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.